Since its inception, the Institute for Work & Health (IWH) has attracted scientists from across different disciplines to conduct research on occupational health, work injury and disability and work-related population health. Sometimes, though, the impact of an IWH scientist’s work moves beyond the work and health field. That is the case for Dr. Dorcas Beaton, who retired in December 2025 from her position with IWH as a senior scientist after almost 35 years. Her career exemplifies how an expertise developed through work and health research — in this case, focused on the measurement of upper extremity musculoskeletal disorders (UE MSDs) — spread to the broader field of clinical health outcomes, with far-reaching implications.
IWH: the DASH Outcome Measure, QuickDASH and more
Beaton’s lifelong interest in UE MSDs was piqued in the early 1980s when, as a newly minted occupational therapist, she worked in the orthopaedics department of a hospital in Halifax, N.S. That interest took root when in 1988 she returned home to Toronto and joined St. Michael’s Hospital, working with patients needing reconstructive services to deal with serious upper extremity injuries.
Beaton particularly enjoyed the research side of her work at St. Mike’s and decided to pursue a graduate degree in clinical epidemiology at the University of Toronto. As fate would have it, her application was misfiled, leading to a last-minute entrance interview with the department head, Dr. Claire Bombardier. The year was 1991, and Bombardier had just joined IWH as one of its first three scientists. Bombardier offered her a fellowship at the Institute, and so began Beaton’s career-spanning association with IWH.
Over the next decade, while Beaton completed her master’s and PhD, she, Bombardier and others at IWH conducted seminal research into UE MSDs and outcome measurement. That research took them into several large Ontario workplaces, including General Motors (GM) in Oshawa, Dofasco Industries in Hamilton, and the Toronto Star.
At GM and Dofasco, it soon became clear to the research team that it didn’t have a proper tool for measuring UE pain and functioning that fit its purposes. “In the late 1990s, the world was starting to recognize that we needed self-reported measures that picked up on the issues of most importance to patients,” says Beaton. “At that time, although there were measures specific to the elbow or shoulder or hand, we didn’t have a measure for upper extremities as a whole. At GM and Dofasco, as would be the case in many workplaces, what mattered to workers and the employer were the effects of work on the arm as a whole, not on a specific joint. They needed a measure that captured any or multiple MSDs in the upper limb.”
In a joint effort between IWH and the American Academy of Orthopedic Surgeons (AAOS), a 12-member team that included Bombardier as the IWH lead and Beaton as a core member developed the Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure. Launched in 1996, the DASH is a patient-report, 30-item questionnaire designed to measure symptoms and physical function of a whole upper limb. It can be used to assess symptoms and functioning at a point in time, and to evaluate and measure change over time.
Beaton began conducting research in 1997 related to UE MSDs at The Star, Toronto’s largest daily newspaper. Beaton’s part of the Star study became the basis of her PhD thesis. She asked Star workers with UE MSDs how they would know if they are better.. Based on her findings, she then set out to determine if the DASH captured what it needed to capture. Her research concluded it did.
Beaton defended her PhD in May 2000. That same year, she and two other students co-authored a journal article on the cross-cultural adaptation of self-report measures. The article laid out a step-by-step process for translating self-report tools into different languages for different cultural contexts. It recognizes that a measure’s items must not only be translated well linguistically but also culturally. That is, for example, an item that asks about the ability to prepare a meal or get dressed might measure very different types of functioning depending on the culture in which the activity is taking place. That paper is one of IWH’s most highly cited journal articles. According to Google Scholar, as of the end of 2025, the article had been cited over 18,000 times.
The longevity, widespread use and success of the DASH and QuickDASH have been well-documented by IWH, including in a 2015 impact case study and in a 2016 article and videocelebrating the 20th anniversary of the DASH. Beaton’s contributions to the DASH and QuickDASH were also instrumental in her receiving a lifetime achievement award from the International Federations of Societies for Hand Therapy in March 2025.
Under Dorcas’s leadership, the DASH team continued to conduct research to ensure the strong measurement properties of the DASH Outcome Measure and QuickDASH and supported the use and widespread uptake of these tools with updated manuals, an information-rich website and other outreach measures,
says Bombardier, now retired from her career as a renowned and widely published clinical researcher, rheumatologist and professor herself. As a result, the DASH tools are used around the world to this day by clinicians who trust the validity and reliability of these patient-report measures.
IWH is where Beaton developed a keen interest in self-reported health outcome measures, especially those related to MSDs, and where she gained a deep appreciation of the importance of knowledge transfer and exchange (KTE) in ensuring research and tools are taken up and applied correctly by intended users. All of this informed the very important work she went on to do for OMERACT.
OMERACT: Core outcome sets and the tools to measure them
Established in 1992, OMERACT (Outcomes Measures in Rheumatology) is an international, non-profit organization. It aims to standardize how clinicians and researchers measure progress in health outcomes among people with autoimmune and musculoskeletal diseases (e.g., arthritis, lupus, etc.). OMERACT does this by creating consensus-based core outcome sets—that is, a checklist of outcomes (i.e., pain, joint swelling, work)—to be included in studies related to a defined field. This allows researchers to more easily compare studies—apples to apples
—and pool them in systematic reviews and meta-analyses to create stronger and more significant findings.
When we do systematic reviews or any other type of study that pulls evidence together, which is the pinnacle of research when guiding decision-makers about the best policy, practice or treatment, the more studies that can be included, the better. It makes a systematic review’s recommendations that much stronger. But studies can only be included if they are measuring the same thing,
explains Beaton. It’s ridiculous the amount of research waste that goes on because clinical trials and other types of studies aren’t using the same outcome sets. That’s what OMERACT is addressing, this waste. We are providing a solid foundation for clinical trials that will be reviewed in the future, making sure that the impacts of the treatments being studied are measured in a relevant, trustworthy and precise manner.
During her roughly 25 years of work at OMERACT, Beaton held numerous management and working group roles, but the work Beaton was (and still is) most passionate about at OMERACT is the development of consistent methods for choosing the best tool for measuring particular core outcomes. A lot of people are involved in OMERACT. We have 40-odd working groups, each designing a core set of outcomes and core measures,
says Beaton. My part, which is threaded through these working groups, is determining the method for choosing the right measure, given the core outcomes and study context. As much as we need to use rigorous methods for clinical trials, we also need rigorous methods for choosing measures. You can’t just pick one off the shelf and assume it will work well.
Beaton’s focus on choosing the right tool to measure core outcomes came 10 days after she defended her PhD thesis, when she was asked to present her thesis at the 2000 biannual OMERACT conference in France. In that presentation, she shared her system for classifying studies that evaluate the ability of an outcome measure to accurately describe change (called a tool’s responsiveness
) and, ultimately, allow researchers to identify measures capable of finding minimally clinical important differences (MCIDs). MCIDs are patient-derived scores that reflect changes as a result of a clinical intervention that are significant and truly matter to patients (e.g., pain, mobility).
Beaton developed a cube of discrimination
to help researchers and clinicians better understand and sort studies and a measure’s responsiveness. People still talk about that cube 25 years later,
says Beaton. I think it’s because it was accessible. And that speaks to the power of KTE, which is something that was drummed into me from the outset at IWH.
Beaton brought this KTE lens to all of her work at OMERACT. (KTE refers to the process of exchange between researchers and knowledge users, designed to make relevant research information available.) That included her role as an editor and writer of the second edition of The OMERACT Handbook. The handbook outlines standards, principles and step-by-step methods for developing, evaluating and endorsing core outcome sets and the instruments to measure them for use in clinical trials and other health research. A revised 2025 version was made publicly available in early 2026.
It was at OMERACT that Beaton’s passion for developing and choosing patient-oriented health outcome measures had, one could argue, the biggest impact. Recognized as an international leader, OMERACT has published more than 1,000 scientific publications and completed 17 core outcome sets. And, most important, according to 2020 systematic review, the core outcome sets are beginning to be taken up by researchers in their clinical studies, to varying degrees depending on the rheumatic illness.
The uptake was highest in studies of rheumatic arthritis (RA)—an impressive 81 per cent. That means 81 per cent of RA studies include the same core outcomes among its full range of outcomes, a level of uniformity that would be enviable to researchers in many other fields. The uptake was lower, but still encouraging, in studies of psoriatic arthritis (59 per cent), systemic sclerosis (50 per cent), and hip or knee osteoarthritis (45 per cent), among other examples.
Dorcas’s work on standardizing rigorous methods for developing core health outcome sets at OMERACT means high-quality, patient-important core outcome sets can be developed faster and implemented sooner in clinical trials around the world,
says Dr. Peter Tugwell, a professor of medicine, epidemiology and community medicine at the University of Ottawa, a practising rheumatologist at The Ottawa Hospital, and chair of OMERACT’s Management Group. During Dorcas’s term as chair of the OMERACT Methods Working Group, her leadership and commitment were central to the evolution of OMERACT’s methodology. This allows us to ensure that the most relevant outcomes and the best instruments get into the hands of clinical trialists and researchers — ones they can have confidence in. From there, future trials and clinical guidelines for the care of people with arthritis can be informed by the outcomes that matter the most.
From playing a key part in the development of a measure of upper-limb function to then being at the centre of a global effort to agree on a common set of patient outcomes in rheumatic arthritis research and treatment, Beaton was driven by a steadfast focus on rigorous methods, combined with a commitment to ensuring the impact of research. At the core, she believed that the research and clinical world needed to make sure that what was measured was meaningful to patients, and that what patients reported was treated with care—in her words, not wasted
. And that depended on the work, sometimes decades long, to make sure measures are robust and used widely.